Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

$FLGC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $FLGC alert in real time by email
SC 13D/A 1 ef20040315_sc13da.htm SC 13D/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
AMENDMENT NO. 5 TO
SCHEDULE 13D
 
Under the Securities Exchange Act of 1934
 
Flora Growth Corp.
(Name of Issuer)
 
Common Shares, no par value
(Title of Class of Securities)

339764102
(CUSIP Number)
 
Clifford Starke
Pia Porras 75 San Francisco
Panama City, Panama
 
With a copy to:
 
Richard Raymer
Dorsey & Whitney LLP
66 Wellington Street W., Suite 3400
Toronto, Ontario M5K 1E6 Canada
(416) 367-7370
 
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 15, 2024
(Date of Event which Requires Filing of this Statement)
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
 
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 


CUSIP No. 339764102
 
1
NAMES OF REPORTING PERSONS
 
 
Clifford Starke (the “Reporting Person”)
 
 
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
 
(b)
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
SOURCE OF FUNDS (SEE INSTRUCTIONS)
 
 
PF and OO
 
 
 
 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
 
Not Applicable
 
 
 
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
Canada
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER
 
 
3,850,886
 
 
 
 
8
SHARED VOTING POWER
 
 
0
 
 
 
 
9
SOLE DISPOSITIVE POWER
 
 
3,850,886
 
 
 
 
10
SHARED DISPOSITIVE POWER
 
 
0
 
 
 
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
3,850,886
 
 
 
 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
NOT APPLICABLE
 
 
 
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
 
19.1%(1)
 
 
 
 
14
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
 
CO
 
 
 
 


(1)
The percentages used herein are calculated based upon 18,511,898 outstanding shares of the Issuer as of December 15, 2024, plus 1,603,984 shares underlying unvested stock appreciation rights owned by the Reporting Person.


CUSIP No. 339764102
 
Reference is hereby made to the statement on Schedule 13D filed with the Securities and Exchange Commission on January 6, 2023 (the “Schedule 13D”), with respect to the Common Stock, no par value (the “Common Stock”), of Flora Growth Corp., an Ontario Corporation (the “Issuer”), as amended on April 21, 2023, November 15, 2023, and April 15, 2024, and September 11, 2024. Capitalized terms not otherwise defined herein are used as defined in the Schedule 13D, as amended. The Reporting Person hereby amends and supplements the Schedule 13D as follows.

Item 1.
Security and Issuer
 
(a)
Title of Class of Securities:
 
Common Shares, no par value
 
(b)
Name of Issuer:
 
Flora Growth Corp., an Ontario corporation
 
(c)
Address of Issuer’s Principal Executive Offices:
 
3230 W. Commercial Blvd., Suite 180
Fort Lauderdale, FL 33309
 
Item 2.
Identity and Background
 
(a)
Name of Reporting Person:
 
Clifford Starke
 
(b)
Principal Business Address:
 
The principal business address of the Reporting Persons is: 3230 W. Commercial Blvd., Suite 180, Fort Lauderdale, FL 33309
 
(c)
Occupation, Employment and Other Information:
 
The Reporting Person is a director and the Chief Executive Officer of the Issuer.
 
(d)
Criminal convictions:
 
The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
 
(e)
Civil proceedings:
 
The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which the Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
 
(f)
Citizenship:
 
Canada
 
Item 3.
Source and Amount of Funds or Other Consideration

PF and OO


Item 4.
Purpose of Transaction
 
The transactions described in Item 5(c) below were made in the ordinary course of business and the Reporting Person has no plans or proposals regarding the acquisition or disposition of securities of the Issuer outside of the ordinary course of business that would result in an extraordinary corporate transaction, a sale or transfer of material assets of the Issuer or its subsidiaries, a change in the current board of directors or management of the Issuer, including the number or term of existing directors or to fill any vacancies on the board of directors of the Issuer, any material change in the present capitalization or dividend policy of the Issuer, any other material change in the Issuer’s business or corporate structure, any changes to the Issuer’s charter, bylaws or instruments corresponding thereto or any other actions which may impede the acquisition of control of the Issuer by any person, any action to cause a class of the Issuer to be delisted from a national securities exchange or cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, any action resulting in eligibility for termination of registration of the Issuer’s securities pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended, or any other similar action.
 
Item 5.
Interests in Securities of the Issuer:
 

(a)
and (b).  As of December 15, 2024, the Reporting Person holds the following shares of Common Stock:
 
Number of shares as to which the Reporting Person has:
 

(i)
Sole power to vote or to direct the vote:  3,850,886
 

(ii)
Shared power to vote or to direct the vote: 0
 

(iii)
Sole power to dispose or direct the disposition:  3,850,886
 

(iv)
Shared power to dispose or direct the disposition: 0
 

(v)
Aggregate amount of shares beneficially owned:  3,850,886
 

(vi)
Percent of class represented in Item (v) above:  19.1%
 
(c)  On September 13, 2024, the Reporting Person purchased 6,795 shares of the Issuer’s common stock, at $0.95 per share for a total purchase price of $611.55.
 
On December 15, 2024, the Issuer granted 900,000 restricted stock awards, with immediate vesting, to the Reporting Person.
 
(d) None
 
(e) Not applicable
 
Item 6.
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
 
Other than described in this Amended Schedule 13D, to the knowledge of the Reporting Person there are no other contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to the securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option agreements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
 
Item 7.
Materials to be Filed as Exhibits
 
Not applicable


SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
Date: December 17, 2024
 
   
 
/s/ Clifford Starke
 
 
Clifford Starke

 

Get the next $FLGC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FLGC

DatePrice TargetRatingAnalyst
11/25/2024$4.00Buy
Aegis Capital
10/13/2021$10.00Buy
Roth Capital
6/23/2021$6.00Buy
MKM Partners
More analyst ratings

$FLGC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Flora Growth Corp. Closes Acquisition of Australian Vaporizers

    Fort Lauderdale, Florida--(Newsfile Corp. - June 5, 2024) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") has entered into a share purchase agreement (the "Agreement") to acquire of all of the issued and outstanding shares of Australian Vaporizers Pty Limited ("Australian Vaporizers") in exchange for 550,000 Flora common shares, valued at $0.7 million based on the closing price of Flora's common shares on June 3, 2024, subject to working capital adjustments. The transaction closed on June 4, 2024. Australian Vaporizers was founded in 2010 and has become one of the largest online retailers of vaporizers, hardware, and accessories in Australia. It is an online expert for aromathe

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Lifeist Sells Australian Vapes

    TORONTO, June 05, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV:LFST) (FRANKFURT: M5B) (OTC:LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced the sale of Australian Vaporizers Pty Ltd. ("Aussie Vapes"), its wholly owned Australian subsidiary to Flora Growth Corp. (NASDAQ:FLGC) ("Flora"), a U.S.-based consumer-packaged goods and pharmaceutical distributor serving all 50 states and 28 countries. The sale was completed through a share purchase agreement (the "SPA") entered into between Lifeist, as vendor, and Flora Growth Corp, as purchaser, purs

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • TSX Venture Exchange Stock Maintenance Bulletins

    VANCOUVER, BC, June 4, 2024 /CNW/ - TSX VENTURE COMPANIES BULLETIN V2024-1678 CEAPRO INC. ("CZO")BULLETIN TYPE: Plan of Arrangement, Remain Halted, DelistBULLETIN DATE: June 4, 2024TSX Venture Tier 2 Company  TSX Venture Exchange (the "Exchange") has accepted for filing documentation in connection with an arrangement agreement dated December 14, 2023, as amended on January 16, 2024, between Ceapro Inc. ("Ceapro") and Aeterna Zentaris Inc. ("Aeterna"), pursuant to which Aeterna acquired all of the issued and outstanding common shares of Ceapro by way of a plan of arrangement under the Canada Business Corporations Act (the "Arrangement"). Under the terms of the Arrangement, Ceapro shareholder

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FLGC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FLGC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$FLGC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FLGC
SEC Filings

See more

$FLGC
Leadership Updates

Live Leadership Updates

See more
  • Flora Growth Corp. Appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains Compliance with NASDAQ Minimum Bid Requirement

    Fort Lauderdale, Florida--(Newsfile Corp. - June 27, 2023) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a consumer-packaged goods leader serving all 50 states with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, announced today that Clifford Starke has been appointed as Chief Executive Officer to lead its global operations and Dany Vaiman has been appointed as Chief Financial Officer. Mr. Starke, who previously served as President of the Company, takes over for Hussein Rakine, who resigned as CEO but will remain on the Company's Board of Directors. Mr. Rakine expressed his confidence in the appointment, stating, "Clifford's

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Flora Growth Corp. Announces the Appointment of Hussein Rakine as CEO and Member of the Board of Directors

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") a leading cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its board of directors (the "Board") accepted the resignation of Luis Merchan as Chairman of the Board and the Company's Chief Executive Officer (CEO). To fill the vacancies created by Mr. Merchan's resignation, the Board has appointed JustCBD founder, Hussein Rakine, as CEO and member of the board of directors. Of the appointment, former-Chairman and CEO, Luis Merchan said, "At Flora we have consistently placed human capital as a critical part of our M&A strategy. That's why today we are honored to have the former foun

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CBD Oil Market to Hit Nearly US$137 Billion by 2029

    FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 23, 2022 /PRNewswire/ -- The CBD oil market is expected to witness an astounding CAGR of 38.90% from 2021 until 2029, climbing from $9.86 billion to $136.64 billion. There are several reasons behind the projected growth such a growing number of CBD-infused skincare products, increased use of THC and CBD in pain management and treatment, rising sales in both retail stores and online, expanding research, and increasing demand for ingestible products. Governments around the world have also begun opening up more doors for CBD, with a recent Health Canada report suggesting legal framework to broaden retail CBD sales across

    $CGC
    $CRON
    $FLGC
    $OGI
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations

$FLGC
Financials

Live finance-specific insights

See more
  • Flora Growth Sets Third Quarter 2022 Conference Call for November 28, 2022, at 4:30 P.M. ET

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, will host its third quarter 2022 earnings call via webcast on Monday, November 28 at 4:30 p.m. ET. During the webcast, Flora management will deliver financial and operational results for the third quarter ended September 30, 2022, and provide updates on Flora's commercial wholesale operations, house of brands and life sciences division strategies. Following the webcast, Flora management will open the call to analysts, media and investors in a Q&A format. Live Webcast Details Date: Monday, November 28, 2022 Time: 4:30 p.m. ET

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Flora Growth to Host Webcast Discussing M&A Activity and International Market Opportunities - Wednesday, October 26, 2022

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that the Company will be hosting an analyst call on Wednesday, October 26, 2022, at 02:00 p.m. EST via webcast to discuss Flora Growth's recent M&A activity and strategic growth opportunities. The conference call and live webcast will invite analysts to pose questions to Flora and Franchise Global Health's leadership teams regarding the recent announcement of the definitive agreement of acquisition between the two companies and the opportunities within the cannabis industry on the global stage. To access this ca

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Flora Growth Awarded Best M&A Deal at Benzinga Cannabis Capital Conference

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the Company received the Best M&A Deal award at Benzinga's 2022 Cannabis Capital Conference in Chicago. "We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers," said Luis Merchan, Chairman and CEO of Flora. Flora completed the acquisition of JustCBD in February 2022, and it immediately offered the Company an established CPG brand with a por

    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FLGC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more